Literature DB >> 2902836

Glutathione content and gamma-glutamyltranspeptidase activity in squamous cell head and neck cancer xenografts.

H Bier1, W Bergler, S Mende, U Ganzer.   

Abstract

Drug resistance is a major problem in chemotherapy of squamous cell head and neck cancers (SCHNC). Since glutathione (GSH) plays a crucial role in mediating tumor cell resistance against various toxic insults, GSH metabolism in SCHNC xenografts was investigated. Xenografts from lymph node metastases contained markedly higher GSH concentrations compared with those derived from the corresponding primary lesions. After subcurative chemotherapy with cisplatin (DDP), a significant increase of both GSH levels and gamma-glutamyltranspeptidase activity (gamma-GT) was gained in tumor HT1M. Tumor HT3M showed high concentrations of GSH and gamma-GT, although these latter concentrations did not increase following chemotherapy with DDP. These findings suggest a possible impact of GSH metabolism on both the formation of metastases and the phenomenon of drug resistance in SCHNC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902836     DOI: 10.1007/bf00464020

Source DB:  PubMed          Journal:  Arch Otorhinolaryngol        ISSN: 0302-9530


  14 in total

1.  Tissue sulfhydryl groups.

Authors:  G L ELLMAN
Journal:  Arch Biochem Biophys       Date:  1959-05       Impact factor: 4.013

2.  [Critical remarks on chemotherapy of malignant tumors of the head and neck].

Authors:  U Ganzer; H Bier; C Bachert
Journal:  Laryngol Rhinol Otol (Stuttg)       Date:  1987-04

3.  Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues.

Authors:  F Tietze
Journal:  Anal Biochem       Date:  1969-03       Impact factor: 3.365

Review 4.  Changing role of chemotherapy in treatment of head and neck cancer.

Authors:  G M Mead; C Jacobs
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

5.  Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

Authors:  T C Hamilton; M A Winker; K G Louie; G Batist; B C Behrens; T Tsuruo; K R Grotzinger; W M McKoy; R C Young; R F Ozols
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

6.  Reduction in glutathione content of L-PAM resistant L1210 Cells confers drug sensitivity.

Authors:  K Suzukake; B J Petro; D T Vistica
Journal:  Biochem Pharmacol       Date:  1982-01-01       Impact factor: 5.858

Review 7.  Glutathione metabolism as a determinant of therapeutic efficacy: a review.

Authors:  B A Arrick; C F Nathan
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

8.  Pharmacologic reversal of drug resistance in ovarian cancer.

Authors:  R F Ozols
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

9.  Hepatic-mediated elevation and maintenance of metastatic tumor cell glutathione.

Authors:  S Ahmad; A Mulberg; J Aljian; D T Vistica
Journal:  Biochem Pharmacol       Date:  1986-05-15       Impact factor: 5.858

10.  Selective modification of glutathione metabolism.

Authors:  A Meister
Journal:  Science       Date:  1983-04-29       Impact factor: 47.728

View more
  3 in total

1.  Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.

Authors:  Karoline Leonhardt; Rolf Gebhardt; Joachim Mössner; Svetlana Lutsenko; Dominik Huster
Journal:  J Biol Chem       Date:  2009-01-13       Impact factor: 5.157

Review 2.  Chemotherapeutic drug resistance in the management of head and neck cancer.

Authors:  H Bier
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

Review 3.  Targeting Cellular Metabolism Modulates Head and Neck Oncogenesis.

Authors:  Yi-Ta Hsieh; Yi-Fen Chen; Shu-Chun Lin; Kuo-Wei Chang; Wan-Chun Li
Journal:  Int J Mol Sci       Date:  2019-08-14       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.